{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:24:48Z","timestamp":1779236688535,"version":"3.51.4"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T00:00:00Z","timestamp":1495584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T00:00:00Z","timestamp":1495584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s40620-017-0410-1","type":"journal-article","created":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T10:44:05Z","timestamp":1495622645000},"page":"689-699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Positioning novel biologicals in CKD-mineral and bone disorders"],"prefix":"10.1093","volume":"30","author":[{"given":"Lida","family":"Tartaglione","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Pasquali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silverio","family":"Rotondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luisa","family":"Muci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Mazzaferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,24]]},"reference":[{"key":"410_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","volume":"76","author":"K-U Eckardt","year":"2009","unstructured":"Eckardt K-U, Kasiske BL (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 76:S1\u2013S2","journal-title":"Kidney Int"},{"key":"410_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/ckj\/sfv104","volume":"8","author":"M Cozzolino","year":"2015","unstructured":"Cozzolino M, Pasquali M (2015) Where is the link between mineral bone markers and cardiovascular disease in CKD? Clin Kidney J 8:729\u2013731","journal-title":"Clin Kidney J"},{"key":"410_CR3","first-page":"S3","volume":"76","author":"S Moe","year":"2009","unstructured":"Moe S, Dr\u00fceke T, Block GA et al (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease -mineral and bone disorder (CKD-MBD). Kidney Int 76:S3\u2013S130","journal-title":"Kidney Int"},{"key":"410_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J, Goodman W, Martin K, Olgaard K et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945\u20131953","journal-title":"Kidney Int"},{"key":"410_CR5","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.semnephrol.2014.09.006","volume":"34","author":"S Mazzaferro","year":"2014","unstructured":"Mazzaferro S, Tartaglione L, Rotondi S, Bover J, Goldsmith D, Pasquali M (2014) News on Biomarkers in CKD-MBD. Semin Nephrol 34:598\u2013611","journal-title":"Semin Nephrol"},{"issue":"6","key":"410_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy.\u00a0JAMA 285(6):785\u2013795","journal-title":"JAMA"},{"key":"410_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.semnephrol.2009.01.007","volume":"29","author":"PD Miller","year":"2009","unstructured":"Miller PD (2009) Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol 29:144\u2013155","journal-title":"Semin Nephrol"},{"key":"410_CR8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jbmr.2406","volume":"30","author":"SL West","year":"2015","unstructured":"West SL, Lok CE, Langsetmo L, Cheung AM, Szabo E, Pearce D et al (2015) Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res 30:913\u2013919","journal-title":"J Bone Miner Res"},{"key":"410_CR9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/kisup.2013.93","volume":"3","author":"JJ Kazama","year":"2013","unstructured":"Kazama JJ, Iwasaki Y, Fukagawa M (2013) Uremic osteoporosis. Kidney Int Suppl 3:446\u2013450","journal-title":"Kidney Int Suppl"},{"key":"410_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/872193","volume":"2015","author":"S Rotondi","year":"2015","unstructured":"Rotondi S, Pasquali M, Tartaglione L, Muci ML, Mandanici G, Leonangeli C et al (2015) Soluble \u03b1 -Klotho serum levels in chronic kidney disease. Int J Endocrinol 2015:1\u20138","journal-title":"Int J Endocrinol"},{"key":"410_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.abb.2010.06.028","volume":"503","author":"S Mazzaferro","year":"2010","unstructured":"Mazzaferro S, Pasquali M, Pirr\u00f2 G, Rotondi S, Tartaglione L (2010) The bone and the kidney. ArchBiochem Biophys 503:95\u2013102","journal-title":"ArchBiochem Biophys"},{"key":"410_CR12","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1002\/jbmr.1985","volume":"28","author":"NE Lane","year":"2013","unstructured":"Lane NE, Parimi N, Corr M et al (2013) Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: the Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res 28:2325\u20132332","journal-title":"J Bone Miner Res"},{"key":"410_CR13","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2215\/CJN.12871211","volume":"7","author":"RH Yenchek","year":"2012","unstructured":"Yenchek RH, Ix JH, Shlipak MG, Bauer DC, Rianon NJ, Kritchevsky SB et al (2012) Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 7:1130\u20131136","journal-title":"Clin J Am Soc Nephrol"},{"key":"410_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","volume":"20","author":"T Suda","year":"1999","unstructured":"Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345\u2013357","journal-title":"Endocr Rev"},{"key":"410_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.tcb.2004.09.016","volume":"14","author":"FJ Pixley","year":"2004","unstructured":"Pixley FJ, Stanley ER (2004) CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 14:628\u2013638","journal-title":"Trends Cell Biol"},{"key":"410_CR16","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","volume":"289","author":"SL Teitelbaum","year":"2000","unstructured":"Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504\u20131508","journal-title":"Science"},{"key":"410_CR17","doi-asserted-by":"publisher","first-page":"19883","DOI":"10.1074\/jbc.M413274200","volume":"280","author":"X Li","year":"2005","unstructured":"Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J et al (2005) Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883\u201319887","journal-title":"J Biol Chem"},{"key":"410_CR18","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/ki.1984.212","volume":"26","author":"WJ Maierhofer","year":"1984","unstructured":"Maierhofer WJ, Lemann J, Gray RW, Cheung HS. (1984) Dietary calcium and serum 1,25-(OH)2-vitamin D concentrations as determinants of calcium balance in healthy men. Kidney Int 26:752\u20139","journal-title":"Kidney Int"},{"key":"410_CR19","doi-asserted-by":"publisher","first-page":"7260","DOI":"10.1073\/pnas.87.18.7260","volume":"87","author":"N Udagawa","year":"1990","unstructured":"Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T et al (1990) Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 87:7260\u20137264","journal-title":"Proc Natl Acad Sci USA"},{"key":"410_CR20","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1210\/jcem-56-3-572","volume":"56","author":"EM Brown","year":"1983","unstructured":"Brown EM (1983) Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 56:572\u2013581","journal-title":"J Clin Endocrinol Metab"},{"key":"410_CR21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1210\/jcem-50-3-480","volume":"50","author":"B Lund","year":"1980","unstructured":"Lund B, S\u00f8rensen OH, Lund B, Bishop JE, Norman AW (1980) Stimulation of 1,25-Dihydroxyvitamin D Production by Parathyroid Hormone and Hypocalcemia in Man. J Clin Endocrinol Metab 50:480\u2013484","journal-title":"J Clin Endocrinol Metab"},{"key":"410_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S1043-2760(01)00409-X","volume":"12","author":"TJ Gardella","year":"2001","unstructured":"Gardella TJ, J\u00fcppner H (2001) Molecular properties of the PTH\/PTHrP receptor. Trends Endocrinol Metab 12:210\u2013217","journal-title":"Trends Endocrinol Metab"},{"key":"410_CR23","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1210\/er.2004-0006","volume":"26","author":"AB Hodsman","year":"2005","unstructured":"Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST et al (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688\u2013703","journal-title":"Endocr Rev"},{"key":"410_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1210\/er.2003-0024","volume":"26","author":"TM Murray","year":"2004","unstructured":"Murray TM, Rao LG, Divieti P, Bringhurst FR (2004) Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocr Rev 26:78\u2013113","journal-title":"Endocr Rev"},{"key":"410_CR25","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF et al (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207\u20131215","journal-title":"N Engl J Med"},{"key":"410_CR26","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1210\/endo.140.8.6887","volume":"140","author":"SK Lee","year":"1999","unstructured":"Lee SK, Lorenzo JA (1999) Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 140:3552\u20133561","journal-title":"Endocrinology"},{"key":"410_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1084\/jem.49.1.145","volume":"49","author":"W Bauer","year":"1929","unstructured":"Bauer W, Aub JC, Albright F (1929) Studies of calcium and phosphorus metabolism: a study of the bone trabeculae as a readily available reserve supply of calcium. J Exp Med 49:145\u2013162","journal-title":"J Exp Med"},{"key":"410_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s001980200026","volume":"13","author":"MR Rubin","year":"2002","unstructured":"Rubin MR, Cosman F, Lindsay R, Bilezikian JP, Lindsay R, Bilezikian JP et al (2002) The anabolic effects of parathyroid hormone. Osteoporos Int 13:267\u2013277","journal-title":"Osteoporos Int"},{"key":"410_CR29","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1210\/jc.2003-1703","volume":"90","author":"H Dobnig","year":"2005","unstructured":"Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie L-G, Gallagher JC et al (2005) Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970\u20133977","journal-title":"J Clin Endocrinol Metab"},{"key":"410_CR30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S8756-3282(00)00430-0","volume":"28","author":"CP Jerome","year":"2001","unstructured":"Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R (2001) Treatment with human parathyroid hormone (1\u201334) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28:150\u2013159","journal-title":"Bone"},{"key":"410_CR31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1359\/jbmr.2003.18.3.539","volume":"18","author":"J Zanchetta","year":"2003","unstructured":"Zanchetta J, Bogado C, Ferretti J, Wang O, Wilson M, Sato M et al (2003) Effects of teriparatide [recombinant human parathyroid hormone (1\u201334)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539\u2013543","journal-title":"J Bone Miner Res"},{"key":"410_CR32","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa050336","volume":"353","author":"DM Black","year":"2005","unstructured":"Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T et al (2005) One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis. N Engl J Med 353:555\u2013565","journal-title":"N Engl J Med"},{"key":"410_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5414\/CP202001","volume":"52","author":"H Imai","year":"2014","unstructured":"Imai H, Watanabe M, Fujita T, Watanabe H, Harada K, Moritoyo T (2014) Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: a pilot study. Int J Clin Pharmacol Ther 52:166\u2013174","journal-title":"Int J Clin Pharmacol Ther"},{"key":"410_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","volume":"18","author":"PD Miller","year":"2007","unstructured":"Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH (2007) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18:59\u201368","journal-title":"Osteoporos Int"},{"key":"410_CR35","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/oxfordjournals.ndt.a027404","volume":"11","author":"G Coen","year":"1996","unstructured":"Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M et al (1996) Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant 11:813\u2013819","journal-title":"Nephrol Dial Transplant"},{"key":"410_CR36","first-page":"289","volume":"36","author":"FC Barreto","year":"2014","unstructured":"Barreto FC, Barreto DV, Canziani ME, Tomiyama C, Higa A, Mozar A et al (2014) Association between indoxyl sulfate and bone histomorphometry in pre-dialysis chronic kidney disease patients. J Bras Nefrol 36:289\u2013296","journal-title":"J Bras Nefrol"},{"key":"410_CR37","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","volume":"27","author":"K Sumida","year":"2016","unstructured":"Sumida K, Ubara Y, Hoshino J, Mise K, Hayami N, Suwabe T et al (2016) Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. Osteoporos Int 27:1441\u20131450","journal-title":"Osteoporos Int"},{"key":"410_CR38","doi-asserted-by":"crossref","unstructured":"Kalantar-Zadeh K, Shah A, Duong U, Hechter RC, Dukkipati R, Kovesdy CP (2010) Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl 78:S10\u201321","DOI":"10.1038\/ki.2010.189"},{"key":"410_CR39","doi-asserted-by":"publisher","first-page":"F882F889","DOI":"10.1152\/ajprenal.00360.2010","volume":"299","author":"V Lavi-Moshayoff","year":"2010","unstructured":"Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299:F882\u2013F889","journal-title":"Am J Physiol Renal Physiol"},{"key":"410_CR40","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu M-C, Sloan A, Isakova T et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393\u20134408","journal-title":"J Clin Invest"},{"key":"410_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/16852","volume":"397","author":"YY Kong","year":"1999","unstructured":"Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C et al (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315\u2013323","journal-title":"Nature"},{"key":"410_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s774-002-8441-x","volume":"20","author":"S Mochizuki","year":"2002","unstructured":"Mochizuki S, Fujise N, Higashio K, Tsuda E (2002) Osteoclastogenesis inhibitory factor\/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. J Bone Miner Metab 20:14\u201320","journal-title":"J Bone Miner Metab"},{"key":"410_CR43","doi-asserted-by":"publisher","first-page":"S148","DOI":"10.1359\/jbmr.2001.16.1.148","volume":"16","author":"S Morony","year":"2001","unstructured":"Morony S, Lu J, Capparelli C, Dustan C, Lacey DL, Kostenuik PJ (2001) Osteoprotegerin (OPG) prevents bone loss in a rat model of glucocorticoid-induced osteopenia. J Bone Miner Res 16:S148","journal-title":"J Bone Miner Res"},{"key":"410_CR44","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"410_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161","journal-title":"J Bone Miner Res"},{"key":"410_CR46","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471\u20131479","journal-title":"J Bone Miner Res"},{"key":"410_CR47","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren \u00d6, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S et al (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829\u20131835","journal-title":"J Bone Miner Res"},{"key":"410_CR48","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40620-016-0334-1","volume":"30","author":"F Festuccia","year":"2016","unstructured":"Festuccia F, Jafari MT, Moioli A, Fofi C, Barberi S, Amendola S et al (2016) Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol 30:271\u2013279","journal-title":"J Nephrol"},{"key":"410_CR49","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1210\/jc.2014-1154","volume":"99","author":"CL Chen","year":"2014","unstructured":"Chen CL, Chen NC, Hsu CY, Chou KJ, Lee PT, Fang HC et al (2014) An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab 99:2426\u20132432","journal-title":"J Clin Endocrinol Metab"},{"key":"410_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s41232-016-0016-3","volume":"361","author":"R Kawakami","year":"2016","unstructured":"Kawakami R, Nakagami H, Noma T, Ohmori K, Kohno M, Morishita R (2016) RANKL system in vascular and valve calcification with aging. Inflamm Regen 361:10","journal-title":"Inflamm Regen"},{"key":"410_CR51","doi-asserted-by":"publisher","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","volume":"6","author":"AR Wijenayaka","year":"2011","unstructured":"Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ (2011) Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 6:e25900","journal-title":"PLoS One"},{"key":"410_CR52","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1034\/j.1399-0004.2003.00036.x","volume":"63","author":"H Hamersma","year":"2003","unstructured":"Hamersma H, Gardner J, Beighton P (2003) The natural history of sclerosteosis. Clin Genet 63:192\u2013197","journal-title":"Clin Genet"},{"key":"410_CR53","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1399-0004.1984.tb00481.x","volume":"25","author":"P Beighton","year":"1984","unstructured":"Beighton P, Barnard A, Hamersma H, van der Wouden A (1984) The syndromic status of sclerosteosis and van Buchem disease. Clin Genet 25:175\u2013181","journal-title":"Clin Genet"},{"key":"410_CR54","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1359\/jbmr.080216","volume":"23","author":"X Li","year":"2008","unstructured":"Li X, Ominsky MS, Niu Q-T, Sun N, Daugherty B, D\u2019Agostin D et al (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860\u2013869","journal-title":"J Bone Miner Res"},{"key":"410_CR55","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jbmr.14","volume":"25","author":"MS Ominsky","year":"2010","unstructured":"Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G et al (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25:948\u2013959","journal-title":"J Bone Miner Res"},{"key":"410_CR56","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1002\/jbmr.182","volume":"25","author":"X Li","year":"2010","unstructured":"Li X, Warmington KS, Niu Q-T, Asuncion FJ, Barrero M, Grisanti M et al (2010) Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 25:2647\u20132656","journal-title":"J Bone Miner Res"},{"key":"410_CR57","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1210\/en.2013-1905","volume":"155","author":"X Li","year":"2014","unstructured":"Li X, Niu Q-T, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M et al (2014) Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. Endocrinology 155:4785\u20134797","journal-title":"Endocrinology"},{"key":"410_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19\u201326","journal-title":"J Bone Miner Res"},{"key":"410_CR59","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese M a., Brown JP, Diez-Perez A et al (2014) Romosozumab in Postmenopausal Women with Low Bone Mineral Density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"410_CR60","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"LC Hofbauer","year":"2016","unstructured":"Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE (2016) Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"410_CR61","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/1471-2369-14-219","volume":"14","author":"VM Brandenburg","year":"2013","unstructured":"Brandenburg VM, Kramann R, Koos R, Kr\u00fcger T, Schurgers L, M\u00fchlenbruch G et al (2013) Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Neprhol 14:219","journal-title":"BMC Neprhol"},{"key":"410_CR62","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/ki.2015.194","volume":"88","author":"AR Qureshi","year":"2015","unstructured":"Qureshi AR, Olauson H, Witasp A et al (2015) Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int 88:1356\u20131364","journal-title":"Kidney Int"},{"key":"410_CR63","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/ndt\/gfu301","volume":"30","author":"C Drechsler","year":"2015","unstructured":"Drechsler C, Evenepoel P, Vervloet MG, Wanne C, Ketteler M, Marx N et al (2015) High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: Results from the NECOSAD study. Nephrol Dial Transplant 30:288\u2013293","journal-title":"Nephrol Dial Transplant"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-017-0410-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-017-0410-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-017-0410-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:57Z","timestamp":1777564617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/30\/5\/689\/8371253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,24]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["410"],"URL":"https:\/\/doi.org\/10.1007\/s40620-017-0410-1","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,24]]},"assertion":[{"value":"2 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LT: no conflict of interests to declare; MP: no conflict of interests to declare; SR: no conflict of interests to declare; MML: no conflict of interests to declare; AC: consultant for FMC; SM: clinical investigation fundings from Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}